NAMs and the Next Inflection Point for Imaging Manufacturers

By Dameka Williams, Chief Research & Insights Officer, Science and Medicine Group

For decades, diagnostic imaging manufacturers have anchored their growth strategies to clinical demand, capital cycles, and incremental modality innovation. However, a quieter (and potentially more disruptive) shift is now underway upstream in the life sciences. While often discussed in the context of toxicology or drug discovery, New Approach Methodologies (NAMs) are beginning to reshape expectations for imaging technologies, workflows, and data value across the translational pipeline.

NAMs, including organoids, advanced 3D cell culture, and spheroids, are designed to replace or reduce animal models with more predictive, human relevant systems. Regulatory and funding signals from NIH and other agencies have accelerated their adoption, pushing these models from academic curiosity toward industrial reality.

Why NAMs Matter to Imaging Manufacturers

At first glance, NAMs may appear peripheral to diagnostic imaging. In reality, they introduce new technical and commercial requirements that directly affect imaging vendors:

1. Demand for Higher-Content Imaging

NAM-based models are structurally complex and dynamic. Imaging them requires higher resolution, 3D visualization, multimodal contrast, and longitudinal capture. These are capabilities that typically exceed what traditional 2D assay imaging can deliver. As a result, NAM adoption is driving interest in high-content, high-resolution, and AI-enabled imaging systems across preclinical and translational settings.

2. Expansion of Imaging Beyond the Clinic

NAMs blur the line between research tools and clinical decision support. Patient-derived organoids are already being explored as functional diagnostics in oncology and rare disease, testing therapeutic response ex vivo before treatment decisions are made. This shifts imaging value upstream, into R&D and translational workflows that historically sat outside the core diagnostic imaging market.

3. Software and Analytics Become Strategic Differentiators

The imaging challenge in NAMs is no longer image capture alone; it’s interpretation. Complex morphology, time-series data, and multi-parameter outputs demand AI-driven analysis, cloud-based workflows, and interoperability with omics and clinical data. For imaging manufacturers, software and analytics are becoming as critical as hardware performance.

A Market Re-Architecture, Not a Feature Upgrade

The most important implication of NAMs is strategic. Manufacturers that position imaging as an integrated component of NAM workflows (rather than a standalone instrument) will be better aligned with how budgets, validation standards, and purchasing decisions are evolving. Those who recognize this shift early will shape the next decade of diagnostic and preclinical imaging demand.

Continue Exploring the Future of NAMs

New Approach Methodologies (NAMs) are not evolving in isolation—they are reshaping research, diagnostics, and technology strategies across the scientific ecosystem.

This blog is part of Science and Medicine Group’s 4-part NAM series, bringing together perspectives from BioInformatics, SDi, IMV, and Kalorama to help you understand where this shift is headed and how to respond.

Click Here to Explore Science & Medicine Group’s NAM Insights & Full Blog Series.

Science & Medicine Group, #1 in NAM Intelligence